Biocon Biologics Garners $75m ADQ Investment

Biocon Subsidiary Now Valued At More Than $4bn After Private Equity Deal

Biocon has secured the latest in a series of investments in its Biocon Biologics subsidiary, from Abu Dhabi based ADQ. The transaction, worth around $75m, values the biosimilars unit at $4.17bn.

Money Dollars Injection Investment
Biocon Biologics has received a further injection of capital • Source: Shutterstock

Biocon has secured a further investment in its Biocon Biologics subsidiary from Abu Dhabi based private equity group ADQ, “one of the region’s largest holding companies.”

The INR5.55bn ($75.7m) investment – which comes in exchange for a 1.80% minority stake in Biocon Biologics – values the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business